Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

ENGN US Equity

enGene Therapeutics Inc.Health Care · Biological Products, (No Diagnostic Substances) · CIK 1980845 · FY ends Oct 31
$1.78
+0.01 (+0.56%)
USD · as of 2026-08-21 · marketstack
DateEventWhat happened / filerSource
2026-08-1413G/ASchedule 13G amendment — ≥5% beneficial owner (passive) · by PERCEPTIVE ADVISORS LLCsec.gov ↗
2026-08-1413G/ASchedule 13G amendment — ≥5% beneficial owner (passive) · by Venrock Healthcare Capital Partners III, L.P.sec.gov ↗
2026-08-1413G/ASchedule 13G amendment — ≥5% beneficial owner (passive) · by Deep Track Capital, LPsec.gov ↗
2026-08-1313G/ASchedule 13G amendment — ≥5% beneficial owner (passive) · by Invus Global Management, LLCsec.gov ↗
2026-08-1213G/ASchedule 13G amendment — ≥5% beneficial owner (passive) · by Blue Owl Capital Holdings LPsec.gov ↗
2026-08-118-K 8.01Other eventssec.gov ↗
2026-07-2213GSchedule 13G filed — ≥5% beneficial owner (passive) · by ACORN BIOVENTURES, L.P.sec.gov ↗
2026-07-178-K 7.01Regulation FD disclosuresec.gov ↗
2026-07-168-K 7.01Regulation FD disclosuresec.gov ↗
2026-07-168-K 5.02Departure/election of directors or officers; compensationsec.gov ↗
Source: SEC EDGAR (public domain) · history starts 2026-07-16

Every row is a filed document, checked against its EDGAR index.